Novartis combi approach will strengthen COPD drug franchise
This article was originally published in Scrip
Executive Summary
While Novartis has attracted US and Japanese approvals for its COPD treatment indacaterol (inhalation powder), which will be marketed as Arcapta Neohaler and Onbrez Inhalation, respectively, it is the compound's potential in combination therapies that will underpin any blockbuster opportunity (ScripIntelligence.com, 4 July, 2011 and 4 July, 2011). Indacaterol's new approvals follow its EU authorisation as Onbrez Breezhaler in December 2009 (ScripIntelligence.com, 8 December 2009).
You may also be interested in...
Boehringer Ingelheim: Olodaterol set for US approval
The FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 15-1 in favor of approval of olodaterol 5µg as a once-daily maintenance bronchodilator for chronic obstructive pulmonary disease (COPD) (see story: FDA reviewers: Bronchodilation somewhat modest for BI’s olodaterol in COPD).
10-year old Spiriva helps asthmatics blow out the candles
COPD therapy Spiriva, now with a decade of use behind it, may also have a role in treating uncontrolled asthma, according to data presented by Boehringer Ingelheim at the 2012 annual meeting of the European Respiratory Society in Vienna, Austria.
Generic Singulair threat becomes reality
As anticipated, Merck is about to face a significant decrease in revenue as the first generic versions of its blockbuster Singulair reach the US market as the FDA has approved the first generic versions of Merck's allergy and asthma drug. Although Merck's strong pipeline is aimed at offsetting the impact of generic erosion, little can be done in the immediate future to stem this loss.